Japan’s Sumitomo merges oncology arms Tolero Pharma, Boston Biomedical

Medical drugs in a pharmacy. Credit: Flickr/epSos .de

Sumitomo Dainippon Pharma (SDP) has merged two of its US-based wholly owned subsidiaries, Tolero Pharmaceuticals and Boston Biomedical, to form Sumitomo Dainippon Pharma Oncology, the company said in a statement Wednesday.

Hiroshi Nomura, CEO of SDP, said merging the two units would help the company make oncology its core business.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter